Piramal Imaging Adds New AD Tracers For Leadership In Neuroimaging Research
This article was originally published in PharmAsia News
Executive Summary
Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.